B-NHL Clinical Trials

6 recruiting

B-NHL Trials at a Glance

12 actively recruiting trials for b-nhl are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Tianjin, Wuhan, and New Brunswick. Lead sponsors running b-nhl studies include Ruijin Hospital, National Cancer Institute (NCI), and Grit Biotechnology.

Browse b-nhl trials by phase

Treatments under study

About B-NHL Clinical Trials

Looking for clinical trials for B-NHL? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-NHL trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-NHL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin's Lymphoma (B-NHL)
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 1

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

B-cell Non-Hodgkins Lymphoma (B-NHL)
Regeneron Pharmaceuticals91 enrolled20 locationsNCT05685173
Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaB-Non Hodgkin Lymphoma+2 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Phase 1

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Non-Hodgkin LymphomaMantle Cell Lymphoma (MCL)CNS Lymphoma+1 more
University of Colorado, Denver68 enrolled1 locationNCT05098613
Recruiting
Phase 1Phase 2

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma (B-NHL)
Cellectis S.A.80 enrolled10 locationsNCT05607420
Recruiting
Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

B-ALLB-NHL
Tongji Hospital20 enrolled1 locationNCT06689917
Recruiting
Phase 1Phase 2

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

AML (Acute Myelogenous Leukemia)Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting
Phase 2

Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

CART TherapyB-NHL
Ruijin Hospital144 enrolled1 locationNCT06695013
Recruiting
Early Phase 1

An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin Lymphoma (B-NHL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology13 enrolled1 locationNCT06693973
Recruiting
Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

B-ALLB-NHL
Shenzhen Genocury Biotech Co., Ltd.20 enrolled1 locationNCT06678282
Recruiting
Phase 1

An Evaluation of LY007 Cell Injection for r/r B-NHL

B-NHL
Ruijin Hospital18 enrolled1 locationNCT06364852
Recruiting
Phase 1

An Evaluation of LY007 Cell Injection for r/r B-NHL

B-NHL
Shanghai Longyao Biotechnology Inc., Ltd.18 enrolled1 locationNCT06279611